Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature

Figure 1 Pathological diagnosis of malignant peritoneal mesothelioma. A and B: Hematoxylin-eosin staining (A: × 200, B: × 400); C and D: Immunohistochemistry: Calretinin (C: × 200, D: × 400).

Figure 2 Abdominal computed tomography scans of the patient. A: A solid mass in the abdomen (8.9 cm × 5.2 cm) in December 2021; B: The targeted lesion shrank from 8.9 cm × 5.2 cm to 4.1 cm × 4.0 cm after five cycles of treatment in April 2022, thus achieving partial response; C: The targeted lesion was enlarged from 4.1 cm × 4.0 cm to 4.4 cm × 4.0 cm in July 2022; D: The targeted lesion (4.4 cm × 4.0 cm) and a new irregular solid mass in the pelvic vesicorectal fossa area were observed in July 2022, and this was evaluated as progressive disease. The orange arrow indicates the primary lesion, whereas the yellow arrow points to the new one.